A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study.
A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study.
复制标题
使用调强放射治疗局部晚期鼻咽癌同步放化疗期间每周与每 3 周顺铂的比较：一项匹配研究
DOI：
10.7150/jca.21357
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Sun R
中科院分区：
文献类型：
--
作者：
Meng DF;Sun R;Peng LX;Huang YS;Yang Q;Luo DH;Hu WH;Xie FY;Luo W;Zhao C;Guo L;Mai HQ;Chen MY;Xie P;Zheng LS;Yang JP;Mei Y;Qiang YY;Xu L;Li CZ;Huang BJ;Qian CN;Sun R
目的：比较局部晚期鼻咽癌（NPC）患者在同步放化疗（CCRT）期间接受顺铂每周一次或3周一次治疗的长期生存结局和急性毒性。研究方法：在2008年11月至2011年8月期间，纳入了241例活检证实的NPC患者，这些患者接受了顺铂和调强放疗（IMRT）。按性别、年龄、T分期、N分期、Karnosky行为评分（KPS）匹配90例接受顺铂30-40 mg/m2每周1次治疗4-7周的患者和90例接受顺铂80 mg/m2每周3次治疗2 ~ 3个周期的患者。鼻咽部靶区66-72戈伊/30-32次，颈部靶区60-66戈伊/30-32次。结果如下：中位随访时间为69个月5年总生存率（OS）、无病生存率（DFS）、局部无复发生存率（LRFS）和无远处转移生存率（DMFS）分别为85.6%和90.0%。顺铂每周一次和3周一次治疗组分别为85.6% vs. 92.6%（P = 0.152）、94.4% vs. 96.7%（P = 0.411）和88.9% vs. 95.6%（P = 0.107）。在单变量和多变量分析中，未发现两个治疗组之间存在统计学显著性生存差异。两组急性毒性发生率相似。结论：在局部晚期NPC患者中，每周或每三周联合顺铂化疗与调强放疗的急性毒性和长期生存结局相似。
Purpose: To compare the long-term survival outcomes and acute toxicity between locoregionally advanced nasopharyngeal carcinoma (NPC) patients who received either weekly or 3-weekly cisplatin during concurrent chemoradiotherapy (CCRT). Methods: Between November 2008 and August 2011, 241 biopsy-proved NPC patients receiving concurrent cisplatin with intensity modulated radiotherapy (IMRT) were included. 90 patients treated with 4-7 weeks of 30-40 mg/m2 cisplatin weekly were matched with 90 patients who received two or three cycles of 80 mg/m2 cisplatin three-weekly by sex, age, T stage, N stage, Karnosky performance score (KPS). IMRT was presented to the nasopharyngeal gross target volume at 66-72 Gy/30-32 fractions and those involved neck area at 60-66 Gy/30-32 fractions. Results: The median follow-up time was 69 months (range, 2-91 months), and the 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) rates were 85.6% vs. 90.0% (P = 0.207), 85.6% vs. 92.6% (P = 0.152), 94.4% vs. 96.7% (P = 0.411), and 88.9% vs. 95.6% (P = 0.107) for the group treated weekly and 3-weekly cisplatin, respectively. No statistically significant survival differences were found between the two treatment groups in both univariate and multivariate analyses. The similar incidence of acute toxicities was observed between two groups. Conclusions: Concurrent cisplatin-based chemotherapy administered weekly or three-weekly in combination with IMRT leads to similar acute toxicities and long-term survival outcomes in locoregionally advanced NPC patients.
登录
查看更多内容
影响因子：
--
作者：
Sarmiento MP;Mejia MB
通讯作者：
Mejia MB
影响因子：
50.5
作者：
Fountzilas, G.;Ciuleanu, E.;Ciuleanu, T.
通讯作者：
Ciuleanu, T.
影响因子：
5.7
作者：
Loong, Herbert H.;Ma, Brigette B. Y.;Chan, Anthony T. C.
通讯作者：
Chan, Anthony T. C.
影响因子：
45.3
作者：
Chan, ATC;Teo, PML;Johnson, PJ
通讯作者：
Johnson, PJ
DOI：
10.1097/coc.0b013e31826b9b1a
发表时间：
2014-02-01
影响因子：
2.6
作者：
Jagdis, Amanda;Laskin, Janessa;Ho, Cheryl
通讯作者：
Ho, Cheryl